297 related articles for article (PubMed ID: 19137020)
21. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
22. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
23. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
Major MB; Camp ND; Berndt JD; Yi X; Goldenberg SJ; Hubbert C; Biechele TL; Gingras AC; Zheng N; Maccoss MJ; Angers S; Moon RT
Science; 2007 May; 316(5827):1043-6. PubMed ID: 17510365
[TBL] [Abstract][Full Text] [Related]
24. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
Benhaj K; Akcali KC; Ozturk M
Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
[TBL] [Abstract][Full Text] [Related]
25. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract][Full Text] [Related]
26. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour.
Fukuzawa R; Holman SK; Chow CW; Savarirayan R; Reeve AE; Robertson SP
J Med Genet; 2010 Nov; 47(11):791-4. PubMed ID: 20679664
[TBL] [Abstract][Full Text] [Related]
27. A genetic study of the role of the Wnt/beta-catenin signalling in Paneth cell differentiation.
Andreu P; Peignon G; Slomianny C; Taketo MM; Colnot S; Robine S; Lamarque D; Laurent-Puig P; Perret C; Romagnolo B
Dev Biol; 2008 Dec; 324(2):288-96. PubMed ID: 18948094
[TBL] [Abstract][Full Text] [Related]
28. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
[TBL] [Abstract][Full Text] [Related]
29. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
30. Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas.
Ehrlich D; Bruder E; Thome MA; Gutt CN; von Knebel Doeberitz M; Niggli F; Perantoni AO; Koesters R
Pediatr Dev Pathol; 2010; 13(1):1-8. PubMed ID: 19348510
[TBL] [Abstract][Full Text] [Related]
31. [The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex].
Angers S
Med Sci (Paris); 2007 Nov; 23(11):1025-7. PubMed ID: 18021721
[No Abstract] [Full Text] [Related]
32. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.
Han M; Rivera MN; Batten JM; Haber DA; Dal Cin P; Iafrate AJ
Genes Chromosomes Cancer; 2007 Oct; 46(10):909-13. PubMed ID: 17620295
[TBL] [Abstract][Full Text] [Related]
33. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
34. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.
Haruta M; Arai Y; Sugawara W; Watanabe N; Honda S; Ohshima J; Soejima H; Nakadate H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2008 Aug; 47(8):712-27. PubMed ID: 18464243
[TBL] [Abstract][Full Text] [Related]
35. Genomic imprinting and Wilms' tumor.
Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
[TBL] [Abstract][Full Text] [Related]
36. WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1.
Duhme C; Busch M; Heine E; de Torres C; Mora J; Royer-Pokora B
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e180-e183. PubMed ID: 31876779
[TBL] [Abstract][Full Text] [Related]
37. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
Zirn B; Wittmann S; Graf N; Gessler M
Cancer Lett; 2005 Mar; 220(1):115-20. PubMed ID: 15737694
[TBL] [Abstract][Full Text] [Related]
38. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
39. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Yun K; Molenaar AJ; Fiedler AM; Mark AJ; Eccles MR; Becroft DM; Reeve AE
Lab Invest; 1993 Nov; 69(5):603-15. PubMed ID: 7504120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
